Alzamend Neuro is a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease, Bipolar disorder, Major Depressive Disorder (“MDD”) and Post-Traumatic Stress Disorder (“PTSD”). Our mission is to rapidly develop and market safe and effective treatments to bring aid to the 43+ Million Americans suffering from these debilitating diseases. Our current pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and ALZN002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer’s.
Company Details
- Employees
- 9
- Founded
- -
- Address
- 3480 Peachtree Rd Ne, 2nd Fl
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.alzamend.com
- HQ
- Atlanta, Georgia
Alzamend Neuro Questions
Alzamend Neuro's website is http://www.alzamend.com
Alzamend Neuro's LinkedIn profile is https://www.linkedin.com/company/alzamend-neuro
Alzamend Neuro has
9 employees.
View email and phone details for 9
employees at Alzamend Neuro.
Alzamend Neuro's industry is
Biotechnology Research
Alzamend Neuro's top competitors are
Neuralink,
Zenas Biopharma,
Bavarian Nordic,
Regeneron,
Illumina Ventures,
V-Wave,
Inmed Pharmaceuticals,
Bicara Therapeutics,
Bridgebio,
Lundbeck.
Alzamend Neuro's categories are Biotechnology Research
Alzamend Neuro's founding year is 2016
